Rising
prevalence of chronic diseases due to togavirus is the major factor driving the
rubella diagnostic testing market. Increasing incidences of rubella is a direct
consequence of high transmission ability of togavirus via air. Rubella
infection generally affects children and adults. The infection has serious
implications in pregnant women, which can lead to fetal death or congenital
defects. Increasing demand for MMR vaccines for the protection of children
against rubella and introduction of advance point of care diagnostic
technologies such as BioPlex 2200 MMRV (varicella zoster, rubella, mumps and
measles virus) by Bio Rad Laboratories are additionally propelling the
growth of global rubella diagnostic testing market. In a probe to combat
rubella disease, various government initiatives pertaining to research and
development of advanced diagnostic techniques in emerging countries such as
China and India are carried out, which is in turn expected to propel
growth of market in near future. However, there is no typical drug therapy
available for treatment of rubella in present, which is expected to restrain
the growth of rubella diagnostic testing market over the forecast period.
The overall
rubella diagnostic testing market is categorized on the basis of diagnostic
testing techniques into flow cytometry, latex slide agglutination test,
monoclonal antibodies, immunoassays, serological testing and clinical
evaluation. These tests are typically prescribed for pregnant women along
with women planning to conceive and health professionals who are in
contact with pregnant women. These tests may also be performed for babies born
with congenital defects.
To request a
sample copy or view summary of this report, click the link below:
Geographically,
the entire rubella diagnostic testing market is classified into North America,
Europe, Asia Pacific, Latin America and MEA. As of 2014, Europe was one of the
largest markets in terms of revenue share owing to the increased cases of
rubella infection in this region. According to the Pan American Health
Organization (PAHO) and WHO, Colombia and Latin America are declared free of
rubella infection, as of 2011. However, epidemics of rubella are still present
in developing regions such as Africa and South East Asia. Vaccinations for
rubella are not available in these regions. Thailand, Timor Leste, Macedonia,
Tajikistan and Syria are accounted for largest number of rubella infection
cases as of 2013. Asia Pacific region is expected to register lucrative growth
over the forecast period owing to larger untapped opportunities, increasing
government initiatives for development of novel vaccines and therapies and comparatively
lower cost of production.
The global
rubella diagnostic testing market is highly fragmented due to the engagement of
various established as well as emerging players in the market. Some key players
operating in the market include Ortho Clinical Diagnostics, Merck & Co.,
Siemens AG, GlaxoSmithKline plc., Hoffmann La Roche Ltd., Bio Rad Laboratories,
Inc., BioMerieux SA, Beckman Coulter Inc. and Abbott Laboratories. These
companies are constantly involved in R&D for gaining competitive advantage
in the global market.
Get more
information of Rubella Diagnostic Testing Market on TOC:
http://www.grandviewresearch.com/industry-analysis/rubella-diagnostic-testing-market/request-toc
About
Grand View Research:
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Web:
www.grandviewresearch.com
No comments:
Post a Comment